EPCAM and neoplasm: We also made use of primary human samples of malignant peritoneal ascites and malignant pleural exudates and show that EnAd expressing the EpCAM BiTE can overcome immune‐suppressive effects associated with the tumour microenvironment and can activate endogenous T cells to kill endogenous tumour cells.